{"entity":{"id":"blood-as-a-renewable-sample","kind":"term","name":"Serial blood sampling","aka":[],"tldr":"Blood can often be collected again, but every draw is a new finite specimen whose fraction, handling and collection time determine its meaning.","summary":"Serial blood sampling can follow circulating analytes or cell populations over time. Plasma, serum and blood-cell fractions are different inputs. Circulating material does not preserve the local tissue architecture and cell relationships available from a tissue sample.","asOf":"2026-11-10","links":[{"label":"Razavi et al., matched plasma, white-cell and tumour sequencing, 2019","url":"https://pubmed.ncbi.nlm.nih.gov/31768066/"},{"label":"NCI cell-free DNA collection and processing practices","url":"https://www.protocols.io/view/nci-biospecimen-evidence-based-practices-bebp-cell-dc8k2zuw.pdf"}],"tags":[],"related":["cfdna","ctdna","clonal-haematopoiesis","ctdna-imaging-discordance"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Cell-free DNA includes DNA from non-malignant sources. A plasma variant can originate in a blood-cell clone; matched white-cell DNA and tumour tissue can help assess origin, without eliminating sampling uncertainty. A negative plasma result can reflect low shedding or limited assay sensitivity rather than absence of cancer.","Retain collection time, treatment context, tube, processing delay, fraction, storage, input quantity, assay and detection limit. Repeat collections have practical burdens and provide later biological time points. Comparisons require compatible methods and the same named question.","Plasma is separated from anticoagulated blood, while serum is obtained after clotting. White-cell DNA can supply a comparator; mononuclear-cell fractions support selected immune measurements; plasma proteins can come from multiple tissues. Cell-free DNA includes a tumour-derived subset, circulating tumour DNA. These fractions are not automatically interchangeable. The intended method may require whole blood or a specified separated fraction; those inputs are not automatically interchangeable.","Fictional example: a variant is found in plasma and matched white-cell DNA but not in available tumour tissue. A blood-cell clone is a possible source, alongside assay and sampling uncertainty. One tissue sample may miss a clone. Neither the plasma label nor the negative tissue result alone proves origin.","Like serial weather readings, repeated draws can follow change only when the same question and compatible methods are used. Blood immune cells are not the same population as cells inside a tumour. Low shedding, finite molecules, handling or assay sensitivity can explain a negative plasma result without proving cancer absent; repeatability does not remove collection burdens or consent requirements.","A blood assay starts with a named analyte or cell population, an appropriate collected fraction, processing and a defined measurement. Each draw and derived aliquot has finite volume; repeat draws have practical and health burdens. Outputs may be concentrations, molecule or variant estimates, or cell counts and frequencies. Input adequacy, detection limits and intended-use cutoffs belong to the assay. Wrong tubes, processing delays, cell breakdown, low input and mistaken source assignment can limit results. Monitoring, diagnostic and research uses need their own validation; a circulating result does not map tumour-wide cell composition or tissue localisation, and a negative result does not establish absence of all cancer."],"category":"Diagnostics & imaging"},"route":"/terms/blood-as-a-renewable-sample/","neighbours":{"term":[{"id":"cfdna","kind":"term","name":"Cell-free DNA (cfDNA)","route":"/terms/cfdna/"},{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"ctdna-imaging-discordance","kind":"term","name":"ctDNA and imaging discordance","route":"/terms/ctdna-imaging-discordance/"}],"pathway":[{"id":"clonal-haematopoiesis","kind":"pathway","name":"Clonal haematopoiesis (CHIP)","route":"/pathways/clonal-haematopoiesis/"}]}}